Drugs / Guaifenesin

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Filed US (FDA) — — 2007-09-27

“Perrigo filed its ANDA for Guaifenesin Extended-Release Tablets, 600 mg containing a Paragraph IV Certification with the U.S. Food & Drug Administration.” perrigo.com ↗

Approved US (FDA) MUCINEX — 2002-07-12 fda.gov ↗

Trials 19

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 19 trials
Phase 1 NCT02572375 Oct → Nov 2014 — Nexgen Pharma, Inc Completed No outcome recorded
Phase 1 NCT03642262 Jun → Aug 2013 — Reckitt Benckiser Inc. Completed No outcome recorded
Phase 1 NCT03649750 May → Aug 2013 — Reckitt Benckiser Inc. Completed No outcome recorded
Phase 1 NCT03633487 Oct 2011 — Reckitt Benckiser Inc. Completed No outcome recorded
Phase 1 NCT03633448 Jun → Jul 2011 — Reckitt Benckiser Inc. Completed No outcome recorded
Phase 1 NCT03643575 Jun → Jul 2009 — Reckitt Benckiser Inc. Completed No outcome recorded
Phase 1 NCT03644108 Jun 2009 — Reckitt Benckiser Inc. Completed No outcome recorded
Phase 1 NCT00902707 May 2009 → May 2012 mucus inspissation of respiratory tract University of North Carolina, Chapel Hill Completed No outcome recorded
Phase 1 NCT03642873 May 2007 — Reckitt Benckiser Inc. Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT01537081 Sep 2011 → Mar 2012 respiratory tract infectious disorder Reckitt Benckiser Inc. Completed No outcome recorded
Phase 32 trials
Phase 3 NCT00857987 Apr 2010 → Oct 2011 respiratory tract infectious disorder Azidus Brasil Unknown No outcome recorded
Phase 3 NCT01085721 — viral respiratory tract infection Mantecorp Industria Quimica e Farmaceutica Ltd. Unknown No outcome recorded
Phase 43 trials
Phase 4 NCT06716645 Dec 2024 → Feb 2025 common cold HALEON Completed No outcome recorded
Phase 4 NCT03725085 Jan → Oct 2015 — Reckitt Benckiser Inc. Completed No outcome recorded
Phase 4 NCT00441246 Feb → May 2007 bronchitis, respiratory tract infectious disorder, sinusitis Adams Respiratory Therapeutics Completed No outcome recorded
Phase not applicable4 trials · 2 missed
— NCT07398924 Jan 2022 → Jun 2023 anovulation, female infertility Yuzuncu Yil University Completed No outcome recorded
— NCT02859246 Sep 2016 → Jul 2018 filamentary keratitis Massachusetts Eye and Ear Infirmary Completed No outcome recorded
— NCT01562548 Feb 2012 → May 2013 — GlaxoSmithKline Completed Missed primary
— NCT01062256 Jan → Feb 2010 respiratory tract infectious disorder Wyeth is now a wholly owned subsidiary of Pfizer Completed Missed primary
Comparator or background therapy12 trials
Phase 1 NCT02157649 Comparator Jun → Aug 2014 — Nexgen Pharma, Inc Completed No outcome recorded
Phase 2 NCT01364467 Comparator May 2011 → Mar 2018 chronic rhinitis Virginia Commonwealth University Completed No outcome recorded
Phase 2 NCT01114581 Comparator Apr 2010 → Apr 2011 respiratory tract infectious disorder Reckitt Benckiser Inc. Completed No outcome recorded
Phase 2 NCT01046136 Comparator Dec 2009 → Mar 2010 common cold Reckitt Benckiser Inc. Completed No outcome recorded
Phase 2 NCT00000752 Background ? → Feb 1993 HIV infectious disease, sinusitis National Institute of Allergy and Infectious Diseases (NIAID) Withdrawn No outcome recorded

News releases announcing trial results or a regulatory action · 3

DateIssuerRelease
2018-03-07 Perrigo Company Regulatory Perrigo Announces Final FDA Approval and Planned Launch for the Store Brand OTC Equivalent of Mucinex® DM Maximum Strength Extended Release Tablets perrigo.com ↗
Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has received final approval from the U.S. Food & Drug administration for the store brand OTC equivalent of Mucinex ® DM Maximum Strength (Guaifenesin and Dextromethorphan Hydrobromide Extended-Release Tablets, 1200 mg/60 mg).
2011-11-28 Perrigo Company Regulatory Perrigo Receives Final FDA Approval for Store Brand Equivalent to Generic Version of Mucinex® perrigo.com ↗
Perrigo Company (Nasdaq: PRGO; TASE) today announced that it received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Guaifenesin Extended-Release Tablets, 600 mg.
2007-09-27 Perrigo Company Regulatory Perrigo Confirms Filing for Generic Version of Mucinex® and Announcement of Lawsuit by Adams Respiratory perrigo.com ↗
Perrigo Company (NASDAQ: PRGO)(TASE: PRGO) announced today that it had filed an Abbreviated New Drug Application (ANDA) for Guaifenesin Extended-Release Tablets, 600 mg, a generic version of Mucinex®.

All press releases naming this drug 12 releases

DateIssuerRelease

Evidence & citations 34 cited values

Every value below carries the sentence it was read from. 34 sources stand behind the page.

FieldValueCited text
Known as guaifenesin “Determine and compare the plasma concentrations and safety and tolerability of Guaifenesin and hydrocodone bitartrate when they are administered alone or in combination to...” NCT03642873 ↗
29

“Evaluate the pharmacokinetics (PK), Safety and tolerability of guaifenesin (Mucinex®) in an immediate-release formulation when a single dose is administered in adolescents and...” NCT03633448 ↗

“Administration of IR Tablets combination of Codeine Phosphate/Guaifenesin 20mg/400mg every 4 hours for 12 hours total.” NCT02157649 ↗

“Guaifenesin 200 mg immediate release (IR) tablet thrice (at 0, 4, and 8 hours) by mouth under fasting condition.” NCT03642262 ↗

“Dextromethorphan Hydrobromide, United States Pharmacopeia (USP) 20 milligram (mg) and Guaifenesin, USP 400 mg” NCT06716645 ↗

“Finally, each Transpulmin Syrup contains guaifenesin, which chemically it is a glyceryl ether guaiacol.” NCT02581397 ↗

“Vicks Cough Syrup for Chesty Coughs 15 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water” NCT03643575 ↗

“Mucinex combines immediate-release (IR) and modified-release guaifenesin in a bilayer tablet.” NCT01537081 ↗

“Characterize and assess PK of guaifenesin in Mucinex® 1200 mg ER Bi-Layer Tablet” NCT03633487 ↗

“Guaifenesin - 100mg, Etafedrine hydrochloride 20mg, Succinate doxilamine 6mg.” NCT00857987 ↗

“Mucinex 1200mg (Guaifenesin)given as 2, 600mg tablets” NCT01114581 ↗

Show 19 more sources

Known as Amonidron ChEMBL registry synonym — accepted as the source's own label CHEMBL980 ↗
Known as CVT-2534 ChEMBL registry synonym — accepted as the source's own label CHEMBL980 ↗
Known as Famel ChEMBL registry synonym — accepted as the source's own label CHEMBL980 ↗
Known as Franolyn chesty ChEMBL registry synonym — accepted as the source's own label CHEMBL980 ↗
Known as Gecolate ChEMBL registry synonym — accepted as the source's own label CHEMBL980 ↗
Known as GGE “Guaifenesin (glyceryl guaiacolate ether [GGE]) has been studied as a cough suppressant and as an expectorant; however, published studies to date have failed to find a...” PMID 24003241 ↗ Sep 2013
1

“Observational studies suggest that orally administered guaifenesin (GGE) may thin lower respiratory tract secretions” PMID 26462765 ↗ Oct 2015

Known as Glycerol guaiacolate ChEMBL registry synonym — accepted as the source's own label CHEMBL980 ↗
Known as glyceryl ether guaiacol “Finally, each Transpulmin Syrup contains guaifenesin, which chemically it is a glyceryl ether guaiacol.” NCT02581397 ↗
Known as Glyceryl guaiacolate ChEMBL registry synonym — accepted as the source's own label CHEMBL980 ↗
Known as glyceryl guaiacolate ether “Guaifenesin (glyceryl guaiacolate ether [GGE]) has been studied as a cough suppressant and as an expectorant; however, published studies to date have failed to find a...” PMID 24003241 ↗ Sep 2013
Known as Guaiacol glyceryl ether ChEMBL registry synonym — accepted as the source's own label CHEMBL980 ↗
Known as Guaifenesin component of flowtuss ChEMBL registry synonym — accepted as the source's own label CHEMBL980 ↗
Known as Guaifenesin component of hycofenix ChEMBL registry synonym — accepted as the source's own label CHEMBL980 ↗
Known as Guaifenesin component of mucinex d ChEMBL registry synonym — accepted as the source's own label CHEMBL980 ↗
Known as Guaifenesin component of mucinex dm ChEMBL registry synonym — accepted as the source's own label CHEMBL980 ↗
Known as Guaifenesin component of obredon ChEMBL registry synonym — accepted as the source's own label CHEMBL980 ↗
Known as Guaifenesin component of xtrelus ChEMBL registry synonym — accepted as the source's own label CHEMBL980 ↗
Known as Guaifenesina ChEMBL registry synonym — accepted as the source's own label CHEMBL980 ↗
Known as Guaifenesine ChEMBL registry synonym — accepted as the source's own label CHEMBL980 ↗
Known as Guaifensin ChEMBL registry synonym — accepted as the source's own label CHEMBL980 ↗
Known as Guaiphenesin ChEMBL registry synonym — accepted as the source's own label CHEMBL980 ↗
Known as Humabid ChEMBL registry synonym — accepted as the source's own label CHEMBL980 ↗
Known as Humibid “Guaifenesin (Humibid®) single extended release 1200 mg tablet administered with 240 mL of room temperature water under fasted conditions.” NCT03642873 ↗
Known as Hustosil ChEMBL registry synonym — accepted as the source's own label CHEMBL980 ↗